|
Expression platform
|
human IgG1 |
|
Isotypes
|
Mammalian (human cell) |
| Products description | Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgG1):GMP-V-2019nCoV-SnAb008,
is a potency validated COVID-19 SARS-CoV-2 neutralizing antibody.This This antibodies can either act as positive control in COVID-19 related vaccines and neutralizing antibodies discovery and development,
or act as a benchmark in SARS-CoV-2 neutralization potency assay.
GeneMedi's validated COVID-19 neutralizing antibodies group including:GMP-V-2019nCoV-SnAb001(human IgG1),GMP-V-2019nCoV-SnAb002(human IgM),GMP-V-2019nCoV-SnAb003(human IGA),GMP-V-2019nCoV-SnAb004(mouse IgG1),and GMP-V-2019nCoV-SnAb005(Cynomolgus (Non human primate, NHP) IgG1). |
| Bioactivity validation | Validated in COVID-19 Spike protein and Spike-RBD protein binding affnity.
COVID-19 related neutralizing potency is validated by
1.2019nCoV pseudotyped virus based neutralization assay in 293T-ACE2 effector cell.
2. competitively blocking the binding of ACE-2 receptor with SARS-CoV-2 Spike protein. |
| Purity | Purity: ≥95% （SDS-PAGE） |
| Application | positive control in COVID-19 related vaccines and neutralizing antibodies discovery,
also act as a benchmark in SARS-CoV-2 neutralization potency assay. |
| Predicted Molecular Mass | 48.9&24.2kDa |
| Formulation | Lyophilized from sterile PBS, PH 7.4 |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
